AstraZeneca: Airsupra Demonstrated Statistically Significant and Clinically Meaningful Reduction in the Risk of Severe Exacerbations in Patients With Intermittent or Mild Persistent Asthma in Batura Phase III Trial
October 08, 2024
October 08, 2024
WILMINGTON, Delaware, Oct. 8 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
Independent Data Monitoring Committee recommended trial stop early due to overwhelming efficacy at pre-planned analysis
AstraZeneca's inhaled anti-inflammatory rescue medication AIRSUPRA demonstrated significant benefit compared to albuterol
* * *
Positive high-level results from the BATURA Phase IIIb trial sh . . .
* * *
Independent Data Monitoring Committee recommended trial stop early due to overwhelming efficacy at pre-planned analysis
AstraZeneca's inhaled anti-inflammatory rescue medication AIRSUPRA demonstrated significant benefit compared to albuterol
* * *
Positive high-level results from the BATURA Phase IIIb trial sh . . .